AGN-151586 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate to Severe Glabellar Lines
Conditions
Moderate to Severe Glabellar Lines
Trial Timeline
Jan 5, 2024 → Apr 3, 2024
NCT ID
NCT06151561About AGN-151586 + Placebo
AGN-151586 + Placebo is a phase 1 stage product being developed by AbbVie for Moderate to Severe Glabellar Lines. The current trial status is completed. This product is registered under clinical trial identifier NCT06151561. Target conditions include Moderate to Severe Glabellar Lines.
What happened to similar drugs?
6 of 20 similar drugs in Moderate to Severe Glabellar Lines were approved
Approved (6) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06308198 | Phase 3 | Completed |
| NCT06151561 | Phase 1 | Completed |
| NCT05248880 | Phase 3 | Completed |
Competing Products
20 competing products in Moderate to Severe Glabellar Lines